Min-Ok Ryu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min-Ok Ryu has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Hwa-Young Youn
Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea
13 shared publications - Kyoung-Won Seo
Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine Seoul National University Seoul Republic of Korea
12 shared publications - Se‐Hoon Kim
Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine Seoul National University Seoul Republic of Korea
8 shared publications - Qiang Li
Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, 08826, Republic of Korea
4 shared publications - A Ryung Nam
Seoul National University College of Veterinary Medicine
3 shared publications Byung-Gee Ko
Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University
3 shared publications
Latest Publications
- 3 November 2026
- Published by Wiley in Veterinary and Comparative Oncology
Feasibility of Shallow Whole‐Genome Sequencing‐Based Circulating Tumour DNA Analysis in Canine Multicentric Lymphoma: A Pilot Study
Lymphoma is a common canine malignancy with high morbidity and variable prognosis. Circulating tumour DNA (ctDNA) has emerged as a minimally invasive biomarker for tumour burden, treatment response and prognosis in human lymphoma. However, the feasibility of applying shallow whole‐genome sequencing (sWGS)‐based ctDNA analysis to canine lymphoma remains unclear. In this pilot study, plasma cell‐free DNA (cfDNA) was quantitatively assessed and additional genomic features were evaluated using sWGS in dogs with multicentric lymphoma. cfDNA concentration was significantly higher in dogs with lymphoma ( n = 13) compared with healthy controls ( n = 24) (median 3.18 vs. 0.25 ng/mL; Mann–Whitney U test, p = 0.004). However, total cfDNA concentration was not significantly associated with time to progression (TTP) ( p = 0.055). Tumour fraction (TF), a surrogate for ctDNA, showed preliminary association with clinical outcome, with a shorter median TTP in the high‐TF group than in the low‐TF group (77 vs. 302 days; p = 0.006). Genomic analysis further revealed copy number aberrations (CNAs); notably, gains on chromosome 13 containing the MYC locus were identified in three dogs, all of which belonged to the high‐TF group. Dogs with lymphoma also displayed distinct cfDNA fragmentation profiles, characterized by an enrichment of shorter fragments within the analysed size range and a shift in the highest mean‐profile peak compared with healthy controls. These findings demonstrate the feasibility of sWGS‐based cfDNA analysis in canine lymphoma and suggest that TF may provide clinically relevant information beyond total cfDNA concentration. Validation in a substantially larger, independent cohort is warranted.
- 3 November 2026
- Published by Wiley in Veterinary and Comparative Oncology
Feasibility of Shallow Whole‐Genome Sequencing‐Based Circulating Tumour DNA Analysis in Canine Multicentric Lymphoma: A Pilot Study
Lymphoma is a common canine malignancy with high morbidity and variable prognosis. Circulating tumour DNA (ctDNA) has emerged as a minimally invasive biomarker for tumour burden, treatment response and prognosis in human lymphoma. However, the feasibility of applying shallow whole‐genome sequencing (sWGS)‐based ctDNA analysis to canine lymphoma remains unclear. In this pilot study, plasma cell‐free DNA (cfDNA) was quantitatively assessed and additional genomic features were evaluated using sWGS in dogs with multicentric lymphoma. cfDNA concentration was significantly higher in dogs with lymphoma ( n = 13) compared with healthy controls ( n = 24) (median 3.18 vs. 0.25 ng/mL; Mann–Whitney U test, p = 0.004). However, total cfDNA concentration was not significantly associated with time to progression (TTP) ( p = 0.055). Tumour fraction (TF), a surrogate for ctDNA, showed preliminary association with clinical outcome, with a shorter median TTP in the high‐TF group than in the low‐TF group (77 vs. 302 days; p = 0.006). Genomic analysis further revealed copy number aberrations (CNAs); notably, gains on chromosome 13 containing the MYC locus were identified in three dogs, all of which belonged to the high‐TF group. Dogs with lymphoma also displayed distinct cfDNA fragmentation profiles, characterized by an enrichment of shorter fragments within the analysed size range and a shift in the highest mean‐profile peak compared with healthy controls. These findings demonstrate the feasibility of sWGS‐based cfDNA analysis in canine lymphoma and suggest that TF may provide clinically relevant information beyond total cfDNA concentration. Validation in a substantially larger, independent cohort is warranted.
- Open Access
- 30 September 2026
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 13, 1949754
Case Report: Epitheliotropic cutaneous presentation of multicentric diffuse large B-cell lymphoma in a dog
Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of canine multicentric lymphoma, whereas epitheliotropism is classically associated with cutaneous T-cell lymphoma. A 9-year-old neutered male Chihuahua was diagnosed with stage IVb multicentric lymphoma and achieved complete remission with a UW-25 L-CHOP protocol. However, an upper lip mass, cytologically consistent with lymphoma, developed during remission. Electrochemotherapy was performed for local control and resulted in marked reduction of the lesion. The dog later developed recurrent peripheral lymphadenopathy and multiple progressive cutaneous masses despite various chemotherapy protocols and was euthanized at week 59 because of progressive clinical deterioration. Histopathology confirmed diffuse large cell lymphoma in the submandibular lymph node, whereas the cutaneous lesions showed neoplastic lymphoid infiltration with multifocal epidermal invasion, mimicking epitheliotropic T-cell lymphoma. Immunohistochemistry (IHC) confirmed diffuse CD20 expression in both sites, with CD3 labeling limited to scattered background lymphocytes. These findings supported the interpretation of secondary cutaneous involvement of DLBCL with a highly unusual epitheliotropic pattern and emphasize the importance of IHC for accurate immunophenotypic classification of cutaneous lymphoma lesions.
- 30 September 2026
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 13, 1949754
Open AccessCase Report: Epitheliotropic cutaneous presentation of multicentric diffuse large B-cell lymphoma in a dog
Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of canine multicentric lymphoma, whereas epitheliotropism is classically associated with cutaneous T-cell lymphoma. A 9-year-old neutered male Chihuahua was diagnosed with stage IVb multicentric lymphoma and achieved complete remission with a UW-25 L-CHOP protocol. However, an upper lip mass, cytologically consistent with lymphoma, developed during remission. Electrochemotherapy was performed for local control and resulted in marked reduction of the lesion. The dog later developed recurrent peripheral lymphadenopathy and multiple progressive cutaneous masses despite various chemotherapy protocols and was euthanized at week 59 because of progressive clinical deterioration. Histopathology confirmed diffuse large cell lymphoma in the submandibular lymph node, whereas the cutaneous lesions showed neoplastic lymphoid infiltration with multifocal epidermal invasion, mimicking epitheliotropic T-cell lymphoma. Immunohistochemistry (IHC) confirmed diffuse CD20 expression in both sites, with CD3 labeling limited to scattered background lymphocytes. These findings supported the interpretation of secondary cutaneous involvement of DLBCL with a highly unusual epitheliotropic pattern and emphasize the importance of IHC for accurate immunophenotypic classification of cutaneous lymphoma lesions.
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (4)
Effect of simethicone on visualization quality and capsule transit time during video capsule endoscopy in healthy dogs
Background: Simethicone enhances visualization quality (VQ) during video capsule endoscopy (VCE) in humans, but its effects on VQ and capsule transit time (CTT) in dogs remain unclear. Hypothesis/Objectives: Evaluate the effects of simethicone on VQ and CTT in dogs undergoing VCE. Animals: Fifteen client-owned healthy dogs weighing 3-10 kg. Methods: Prospective, blinded, randomized crossover study. Each dog underwent VCE twice: once with 20 mg (1 mL) simethicone administered 30 minutes before capsule ingestion, and once with 1 mL normal saline as a control. Visualization quality was assessed based on the proportion of mucosa visualized (variable 1), the degree of obscuration by bubbles, debris, blood, or bile (variable 2), and their average (variable 3). Capsule transit time, including gastric transit time (GTT) and small bowel transit time (SBTT), and incomplete study rates also were evaluated. Results: Simethicone significantly improved VQ in the entire small bowel, especially in the proximal segment (P < .05 for all variables). However, no significant differences were observed between protocols in the distal small bowel and stomach. Gastric transit time and SBTT also were not significantly different between protocols. The risk of incomplete studies was not significantly affected by protocol, sex, body weight, or age. Conclusions and clinical importance: Simethicone had region-specific effects on VQ in dogs undergoing VCE, specifically enhancing VQ in the small intestine. These findings provide preliminary evidence of a potential role for simethicone in improving small bowel VQ.
- 1 July 2026
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (4)
Open AccessEffect of simethicone on visualization quality and capsule transit time during video capsule endoscopy in healthy dogs
Background: Simethicone enhances visualization quality (VQ) during video capsule endoscopy (VCE) in humans, but its effects on VQ and capsule transit time (CTT) in dogs remain unclear. Hypothesis/Objectives: Evaluate the effects of simethicone on VQ and CTT in dogs undergoing VCE. Animals: Fifteen client-owned healthy dogs weighing 3-10 kg. Methods: Prospective, blinded, randomized crossover study. Each dog underwent VCE twice: once with 20 mg (1 mL) simethicone administered 30 minutes before capsule ingestion, and once with 1 mL normal saline as a control. Visualization quality was assessed based on the proportion of mucosa visualized (variable 1), the degree of obscuration by bubbles, debris, blood, or bile (variable 2), and their average (variable 3). Capsule transit time, including gastric transit time (GTT) and small bowel transit time (SBTT), and incomplete study rates also were evaluated. Results: Simethicone significantly improved VQ in the entire small bowel, especially in the proximal segment (P < .05 for all variables). However, no significant differences were observed between protocols in the distal small bowel and stomach. Gastric transit time and SBTT also were not significantly different between protocols. The risk of incomplete studies was not significantly affected by protocol, sex, body weight, or age. Conclusions and clinical importance: Simethicone had region-specific effects on VQ in dogs undergoing VCE, specifically enhancing VQ in the small intestine. These findings provide preliminary evidence of a potential role for simethicone in improving small bowel VQ.
- Open Access
- 1 June 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (6)
Recurrent pyuria is associated with shorter progression-free survival in dogs with bladder urothelial carcinoma
Objective: To evaluate the association between pyuria and clinical outcomes in dogs. Methods: Data were collected from 2010 through 2025. Pyuria was defined as ≥ 5 WBCs/hpf in urine sediment. Dogs were stratified according to pyuria frequency (0, 1 to 2, or ≥ 3 episodes) and tumor size (< 3 or ≥ 3 cm). Progression-free survival (PFS) and overall survival were analyzed using Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models. Results: 51 dogs diagnosed with bladder urothelial carcinoma (UC) were included. When stratified by pyuria frequency, dogs with ≥ 3 episodes had a significantly shorter median PFS than dogs without pyuria (175 vs 365 days), whereas dogs with 1 to 2 episodes did not differ significantly from the nonpyuria group. In the multivariable analysis, ≥ 3 pyuria episodes remained a negative prognostic factor for PFS (hazard ratio, 3.57; 95% CI, 1.27 to 10.04) even after accounting for the total number of urinalyses performed. Dogs with pyuria at initial diagnosis had a shorter median overall survival than the nonpyuria group (353 vs 531 days). Conclusions: Dogs with pyuria at initial diagnosis and frequent pyuria (≥ 3 episodes) during the entire treatment period had shorter PFS than dogs without pyuria. Clinical Relevance: This finding parallels observations in human medicine and suggests that pyuria may serve as a clinically useful marker of tumor progression in canine UC.
- 1 June 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (6)
Open AccessRecurrent pyuria is associated with shorter progression-free survival in dogs with bladder urothelial carcinoma
Objective: To evaluate the association between pyuria and clinical outcomes in dogs. Methods: Data were collected from 2010 through 2025. Pyuria was defined as ≥ 5 WBCs/hpf in urine sediment. Dogs were stratified according to pyuria frequency (0, 1 to 2, or ≥ 3 episodes) and tumor size (< 3 or ≥ 3 cm). Progression-free survival (PFS) and overall survival were analyzed using Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models. Results: 51 dogs diagnosed with bladder urothelial carcinoma (UC) were included. When stratified by pyuria frequency, dogs with ≥ 3 episodes had a significantly shorter median PFS than dogs without pyuria (175 vs 365 days), whereas dogs with 1 to 2 episodes did not differ significantly from the nonpyuria group. In the multivariable analysis, ≥ 3 pyuria episodes remained a negative prognostic factor for PFS (hazard ratio, 3.57; 95% CI, 1.27 to 10.04) even after accounting for the total number of urinalyses performed. Dogs with pyuria at initial diagnosis had a shorter median overall survival than the nonpyuria group (353 vs 531 days). Conclusions: Dogs with pyuria at initial diagnosis and frequent pyuria (≥ 3 episodes) during the entire treatment period had shorter PFS than dogs without pyuria. Clinical Relevance: This finding parallels observations in human medicine and suggests that pyuria may serve as a clinically useful marker of tumor progression in canine UC.
- Open Access
- 22 May 2026
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 67 (3) , e70190
CT–MRI Fusion for Radiation Treatment Planning and Serial Imaging of a Canine Maxillofacial Osteosarcoma
A 10‐year‐old poodle with left maxillofacial osteosarcoma received volumetric modulated arc therapy delivering 32 Gy in four fractions. Treatment planning was guided by computed tomography–magnetic resonance imaging (CT–MRI) fusion for precise target delineation near the globe. Serial CT and MRI up to 12 months after treatment showed transient enlargement of intratumoral cysts with fluid–fluid levels immediately after treatment, indicating pseudoprogression, followed by marked tumor regression. Progressive cortical remodeling and re‐ossification restored normal bone contours. These findings present the value of multimodal imaging in radiotherapy planning and follow‐up of head and neck tumors to distinguish pseudoprogression from tumor growth and identify postradiation bone regeneration.
- 22 May 2026
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 67 (3) , e70190
Open AccessCT–MRI Fusion for Radiation Treatment Planning and Serial Imaging of a Canine Maxillofacial Osteosarcoma
A 10‐year‐old poodle with left maxillofacial osteosarcoma received volumetric modulated arc therapy delivering 32 Gy in four fractions. Treatment planning was guided by computed tomography–magnetic resonance imaging (CT–MRI) fusion for precise target delineation near the globe. Serial CT and MRI up to 12 months after treatment showed transient enlargement of intratumoral cysts with fluid–fluid levels immediately after treatment, indicating pseudoprogression, followed by marked tumor regression. Progressive cortical remodeling and re‐ossification restored normal bone contours. These findings present the value of multimodal imaging in radiotherapy planning and follow‐up of head and neck tumors to distinguish pseudoprogression from tumor growth and identify postradiation bone regeneration.
- Open Access
- 3 March 2026
- Published by Springer Nature in Veterinary Research Communications
- Vol. 50 (3) , 187
Deep learning-driven automated detection of canine cardiac murmurs via digital wireless stethoscope auscultation
A heart murmur is a key indicator of cardiovascular disease, making auscultation essential. Nonetheless, its accuracy is influenced by the clinician’s experience and subjective interpretation. This study developed a deep learning–based algorithm (CNN6) for automated detection of heart murmurs using phonocardiogram (PCG) data acquired via a digital wireless stethoscope. A total of 2,269 recordings (over 20 h) from 406 dogs were used for model development and validation, and 297 recordings from 60 dogs were reserved for independent testing. The model achieved 89.9% sensitivity, 92.7% specificity, and 90.9% accuracy, demonstrating diagnostic performance comparable to that of experienced veterinarians. This AI-assisted approach provides a consistent and objective murmur assessment and represents a clinically applicable screening tool for myxomatous mitral valve disease (MMVD), enhancing diagnostic precision, facilitating telemedicine, and promoting the integration of artificial intelligence into veterinary cardiology.
- 3 March 2026
- Published by Springer Nature in Veterinary Research Communications
- Vol. 50 (3) , 187
Open AccessDeep learning-driven automated detection of canine cardiac murmurs via digital wireless stethoscope auscultation
A heart murmur is a key indicator of cardiovascular disease, making auscultation essential. Nonetheless, its accuracy is influenced by the clinician’s experience and subjective interpretation. This study developed a deep learning–based algorithm (CNN6) for automated detection of heart murmurs using phonocardiogram (PCG) data acquired via a digital wireless stethoscope. A total of 2,269 recordings (over 20 h) from 406 dogs were used for model development and validation, and 297 recordings from 60 dogs were reserved for independent testing. The model achieved 89.9% sensitivity, 92.7% specificity, and 90.9% accuracy, demonstrating diagnostic performance comparable to that of experienced veterinarians. This AI-assisted approach provides a consistent and objective murmur assessment and represents a clinically applicable screening tool for myxomatous mitral valve disease (MMVD), enhancing diagnostic precision, facilitating telemedicine, and promoting the integration of artificial intelligence into veterinary cardiology.
- Open Access
- 13 January 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (1) , e70752
Resolution of Noncardiogenic Pulmonary Oedema and Suspected Uraemic Pneumonitis in a Dog With Acute Kidney Injury Treated by Haemodialysis
A 7‐year‐old, 3.44‐kg, spayed female Poodle was referred for acute kidney injury following firocoxib administration. Initial diagnostics revealed severe uraemia, oliguria and elevated C‐reactive protein levels. Despite fluid resuscitation and diuretic therapy, oliguria persisted, necessitating haemodialysis. On Day 2, post‐haemodialysis, the patient developed progressive pulmonary infiltration. The acute onset of tachypnoea, in the absence of cardiac disease or fluid overload, suggested noncardiogenic pulmonary oedema. Differential diagnoses included uraemic pneumonitis, acute respiratory distress syndrome and transfusion‐related acute lung injury. After three haemodialysis sessions, urine output increased to polyuria; however, respiratory symptoms and radiographic abnormalities persisted. By Day 7, pulmonary infiltration had significantly decreased on radiographs, although tachypnoea remained. As polyuria continued, uraemia and radiographic findings progressively improved and tachypnoea resolved by Day 12. The patient was discharged, and by Day 18, follow‐up radiographs confirmed complete resolution of pulmonary changes. In this case report, we documented the serial progression and resolution of severe noncardiogenic pulmonary oedema, successfully managed with haemodialysis and supportive care, highlighting the therapeutic importance of addressing the primary uraemic insult.
- 13 January 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (1) , e70752
Open AccessResolution of Noncardiogenic Pulmonary Oedema and Suspected Uraemic Pneumonitis in a Dog With Acute Kidney Injury Treated by Haemodialysis
A 7‐year‐old, 3.44‐kg, spayed female Poodle was referred for acute kidney injury following firocoxib administration. Initial diagnostics revealed severe uraemia, oliguria and elevated C‐reactive protein levels. Despite fluid resuscitation and diuretic therapy, oliguria persisted, necessitating haemodialysis. On Day 2, post‐haemodialysis, the patient developed progressive pulmonary infiltration. The acute onset of tachypnoea, in the absence of cardiac disease or fluid overload, suggested noncardiogenic pulmonary oedema. Differential diagnoses included uraemic pneumonitis, acute respiratory distress syndrome and transfusion‐related acute lung injury. After three haemodialysis sessions, urine output increased to polyuria; however, respiratory symptoms and radiographic abnormalities persisted. By Day 7, pulmonary infiltration had significantly decreased on radiographs, although tachypnoea remained. As polyuria continued, uraemia and radiographic findings progressively improved and tachypnoea resolved by Day 12. The patient was discharged, and by Day 18, follow‐up radiographs confirmed complete resolution of pulmonary changes. In this case report, we documented the serial progression and resolution of severe noncardiogenic pulmonary oedema, successfully managed with haemodialysis and supportive care, highlighting the therapeutic importance of addressing the primary uraemic insult.
- Open Access
- 2 October 2025
- Published by Springer Nature in BMC Veterinary Research
- Vol. 21 (1) , 1-11
Evaluation of the effectiveness and adverse events of oxycodone as a pain-relieving agent in 103 dogs with tumors: a retrospective study
Background: Oxycodone, a semi-synthetic opioid, has been widely used in human medicine for the management of tumor-related pain due to its potent analgesic properties. This study aimed to evaluate the efficacy and safety of oxycodone in managing tumor-related pain in dogs, addressing the current lack of research on effective analgesic options for canine cancer dogs. Medical records of 103 tumor-bearing dogs treated with oxycodone were retrospectively reviewed. Results: Oxycodone demonstrated an analgesic effect ranging from 23.1 to 63.6%, depending on the anatomical origin of the tumor. Improvement was observed in 67.7% of dogs with metastatic lesions. In the monotherapy group, the mean pain relief score increased from 8.73 ± 1.27 before treatment to 9.65 ± 1.53 after administration (p < 0.0001). In the combination therapy group, score rose from 8.75 ± 1.20 to 9.83 ± 1.87 (p = 0.0002). Across the entire canine patient cohort, the mean pain relief score increased from 8.74 ± 1.23 to 9.74 ± 1.70 following treatment (p < 0.0001). Adverse effects included lethargy (n = 6), diarrhea (n = 2), vomiting (n = 1), tachypnea (n = 1), and stargazing (n = 1). All were self-limiting and resolved after discontinuation of the drug. Conclusions and clinical importance: Oxycodone demonstrated an overall favorable analgesic profile and could be a well-tolerated and promising pain management solution, both as monotherapy and in combination therapy, for tumor-related pain in dogs, including those with advanced-stage tumors.
- 2 October 2025
- Published by Springer Nature in BMC Veterinary Research
- Vol. 21 (1) , 1-11
Open AccessEvaluation of the effectiveness and adverse events of oxycodone as a pain-relieving agent in 103 dogs with tumors: a retrospective study
Background: Oxycodone, a semi-synthetic opioid, has been widely used in human medicine for the management of tumor-related pain due to its potent analgesic properties. This study aimed to evaluate the efficacy and safety of oxycodone in managing tumor-related pain in dogs, addressing the current lack of research on effective analgesic options for canine cancer dogs. Medical records of 103 tumor-bearing dogs treated with oxycodone were retrospectively reviewed. Results: Oxycodone demonstrated an analgesic effect ranging from 23.1 to 63.6%, depending on the anatomical origin of the tumor. Improvement was observed in 67.7% of dogs with metastatic lesions. In the monotherapy group, the mean pain relief score increased from 8.73 ± 1.27 before treatment to 9.65 ± 1.53 after administration (p < 0.0001). In the combination therapy group, score rose from 8.75 ± 1.20 to 9.83 ± 1.87 (p = 0.0002). Across the entire canine patient cohort, the mean pain relief score increased from 8.74 ± 1.23 to 9.74 ± 1.70 following treatment (p < 0.0001). Adverse effects included lethargy (n = 6), diarrhea (n = 2), vomiting (n = 1), tachypnea (n = 1), and stargazing (n = 1). All were self-limiting and resolved after discontinuation of the drug. Conclusions and clinical importance: Oxycodone demonstrated an overall favorable analgesic profile and could be a well-tolerated and promising pain management solution, both as monotherapy and in combination therapy, for tumor-related pain in dogs, including those with advanced-stage tumors.
- Open Access
- 12 August 2025
- Published by Springer Nature in BMC Veterinary Research
- Vol. 21 (1) , 1-13
Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial
Background: Sodium-glucose cotransporter 2 inhibitors are widely used in human medicine for their insulin-independent glucose-lowering effects. However, their clinical efficacy and safety for managing diabetes mellitus in dogs have not been established. This study aimed to evaluate the efficacy and safety of DWP16001, a selective sodium-glucose cotransporter 2 inhibitor, as an adjunct to insulin therapy for client-owned dogs with diabetes mellitus. Methods: This multicenter, randomized, double-blind, placebo-controlled clinical trial involved 61 dogs receiving stable insulin therapy. They were randomly assigned to receive DWP16001 (0.025 mg/kg PO q24h) or placebo for 8 weeks. The changes in the serum fructosamine (weeks 0, 1, 4, and 8) and HbA1c (weeks 0, 4 and 8) concentrations and daily insulin dose were assessed. Safety evaluations included adverse event monitoring, physical examination, body weight measurement, blood gas and ketone analyses, urinalysis, and hematologic and biochemical profiling. Hypoglycemia was detected via blood glucose curve. Results: DWP16001 significantly reduced fructosamine and HbA1c concentrations in the dogs, especially in those with poor baseline glycemic control (fructosamine ≥ 500 µmol/L, HbA1c ≥ 6%). A trend toward reduced insulin requirements was observed in the treatment group without significant weight loss or clinically relevant changes in systolic blood pressure or signs of volume depletion. Asymptomatic hypoglycemia was detected in four dogs receiving DWP16001, but it resolved following insulin dose adjustment. No episodes of diabetic ketoacidosis were recorded, and laboratory parameters remained stable throughout the study. Conclusions: DWP16001 is a safe and effective adjunct to insulin therapy for diabetic dogs, especially those with suboptimal glycemic control. It demonstrated insulin-sparing effects and favorable metabolic safety, necessitating further evaluation in long-term clinical studies.
- 12 August 2025
- Published by Springer Nature in BMC Veterinary Research
- Vol. 21 (1) , 1-13
Open AccessDifferential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial
Background: Sodium-glucose cotransporter 2 inhibitors are widely used in human medicine for their insulin-independent glucose-lowering effects. However, their clinical efficacy and safety for managing diabetes mellitus in dogs have not been established. This study aimed to evaluate the efficacy and safety of DWP16001, a selective sodium-glucose cotransporter 2 inhibitor, as an adjunct to insulin therapy for client-owned dogs with diabetes mellitus. Methods: This multicenter, randomized, double-blind, placebo-controlled clinical trial involved 61 dogs receiving stable insulin therapy. They were randomly assigned to receive DWP16001 (0.025 mg/kg PO q24h) or placebo for 8 weeks. The changes in the serum fructosamine (weeks 0, 1, 4, and 8) and HbA1c (weeks 0, 4 and 8) concentrations and daily insulin dose were assessed. Safety evaluations included adverse event monitoring, physical examination, body weight measurement, blood gas and ketone analyses, urinalysis, and hematologic and biochemical profiling. Hypoglycemia was detected via blood glucose curve. Results: DWP16001 significantly reduced fructosamine and HbA1c concentrations in the dogs, especially in those with poor baseline glycemic control (fructosamine ≥ 500 µmol/L, HbA1c ≥ 6%). A trend toward reduced insulin requirements was observed in the treatment group without significant weight loss or clinically relevant changes in systolic blood pressure or signs of volume depletion. Asymptomatic hypoglycemia was detected in four dogs receiving DWP16001, but it resolved following insulin dose adjustment. No episodes of diabetic ketoacidosis were recorded, and laboratory parameters remained stable throughout the study. Conclusions: DWP16001 is a safe and effective adjunct to insulin therapy for diabetic dogs, especially those with suboptimal glycemic control. It demonstrated insulin-sparing effects and favorable metabolic safety, necessitating further evaluation in long-term clinical studies.
- Open Access
- 15 April 2025
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 23 (3) , 377-387
Auranofin Induces ER Stress‐Mediated Apoptosis, and Its Combination With Bortezomib Elicits Paraptosis‐Like Cell Death in Malignant Canine Mammary Tumour Cells
Canine mammary tumours (CMT) are common in female dogs, often associated with malignancy and limited responses to conventional therapies. This study explores the potential of Auranofin (AF) in malignant CMT, focusing on its ability to induce distinct cell deaths. AF inhibited thioredoxin reductase (TrxR) activity, cell proliferation, and colony formation across malignant CMT cell lines, demonstrating significant anticancer effects. In AF‐sensitive cell lines (CMT‐U27, CHMm, and CHMp), 0.5–2 μM AF induced endoplasmic reticulum (ER) stress‐mediated apoptosis, while concentrations above 3 μM caused near‐complete cell death via additional proteasome inhibition. However, in AF‐resistant cell lines (CIPp and CIPm), AF concentrations required for near‐complete cell death were higher, expected to be challenging to achieve clinically. Therefore, we combined sublethal doses of AF (~2 μM) with the proteasome inhibitor Bortezomib (Bz) in these cells. The combination exhibited synergistic cytotoxicity and induced extensive cytoplasmic vacuolation. Live‐cell staining revealed the ER origin of vacuoles, and cycloheximide pretreatment inhibited both vacuolation and AF + Bz‐induced cell death, indicating features of paraptosis. While apoptosis could not be excluded, it was classified as paraptosis‐like cell death occurring concurrently with apoptosis. Further analysis supported that this cell death is related to enhanced ER stress from AF‐induced TrxR inhibition and Bz‐induced proteasome inhibition. Based on these findings, we propose AF alone or combined with Bz as a promising therapeutic strategy for malignant CMT. Our findings highlight AF's potential to induce ER stress‐mediated apoptosis and paraptosis‐like cell death in canine cancer cells, expanding therapeutic options for targeting cancers in dogs.
- 15 April 2025
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 23 (3) , 377-387
Open AccessAuranofin Induces ER Stress‐Mediated Apoptosis, and Its Combination With Bortezomib Elicits Paraptosis‐Like Cell Death in Malignant Canine Mammary Tumour Cells
Canine mammary tumours (CMT) are common in female dogs, often associated with malignancy and limited responses to conventional therapies. This study explores the potential of Auranofin (AF) in malignant CMT, focusing on its ability to induce distinct cell deaths. AF inhibited thioredoxin reductase (TrxR) activity, cell proliferation, and colony formation across malignant CMT cell lines, demonstrating significant anticancer effects. In AF‐sensitive cell lines (CMT‐U27, CHMm, and CHMp), 0.5–2 μM AF induced endoplasmic reticulum (ER) stress‐mediated apoptosis, while concentrations above 3 μM caused near‐complete cell death via additional proteasome inhibition. However, in AF‐resistant cell lines (CIPp and CIPm), AF concentrations required for near‐complete cell death were higher, expected to be challenging to achieve clinically. Therefore, we combined sublethal doses of AF (~2 μM) with the proteasome inhibitor Bortezomib (Bz) in these cells. The combination exhibited synergistic cytotoxicity and induced extensive cytoplasmic vacuolation. Live‐cell staining revealed the ER origin of vacuoles, and cycloheximide pretreatment inhibited both vacuolation and AF + Bz‐induced cell death, indicating features of paraptosis. While apoptosis could not be excluded, it was classified as paraptosis‐like cell death occurring concurrently with apoptosis. Further analysis supported that this cell death is related to enhanced ER stress from AF‐induced TrxR inhibition and Bz‐induced proteasome inhibition. Based on these findings, we propose AF alone or combined with Bz as a promising therapeutic strategy for malignant CMT. Our findings highlight AF's potential to induce ER stress‐mediated apoptosis and paraptosis‐like cell death in canine cancer cells, expanding therapeutic options for targeting cancers in dogs.